News

About 5,000 women living with HIV in the U.S. give birth each year.

Antibodies level went after a third dose but the response was weaker among those being treated with fingolimod than among those taking anti-CD20 treatments such as Rituxan.

The Biosimilars Forum Board of Directors recently appointed Juliana M. Reed as its new executive director and Formulary Watch got the scoop from Reed first hand.

The conclusion of the pre-print meta-analysis is that small effect of "nonpharmaceutical interventions" on COVID-19 mortality rates did not outweigh the effects of lockdowns.

A Kaiser Family Foundation survey found that all the responding programs had at least one initiative to expand behavioral health services.

FDA approved the first generic version of Restasis 0.05% eye drops to increase tear production in patients whose production is suppressed due to dry eye.

German research team finds that 11% of those who quit the drug for pregnancy had “clinically meaningful disability” one-year postpartum. They don’t advise against quitting the drug but say their findings suggest that patients should be informed of the risk.

Biden is reviving the program he headed as vice president with the goal of reducing the cancer mortality rate and improving the experience of patients and their loved ones.

A Congressional Budget Office report documented the wide range in prices paid for hospital and physician services. Hospital inpatient services were the priciest in Massachusetts and cheapest in Arkansas

Pfizer and BioNTech initiated an application yesterday (Feb. 1) for emergency use authorization (EUA) of their COVID-19 vaccine for children ages 6 months through 4 years.

Results of an AstraZeneca trial presented at a recent ASCO meeting sow hopes for a new treatment for patients diagnosed with unresectable hepatocellular carcinoma, the most common type of liver cancer.

Research shows similar results between those with HIV and those without, although 15 years post-kidney transplant, outcomes were worse for people with HIV.

FDA is requiring postmarketing surveillance studies to further assess the risk of myocarditis and pericarditis from the vaccine, which is being sold under the brand name Spikevax.

Findings reported in JAMA Network Open show that patients with chronic hepatitis B didn’t reap the benefits of price competition as the number of generic suppliers of the antiviral increased from one to 11.

Staffing challenges within the healthcare revenue cycle impede productivity, increase burnout.

A Congressional Budget Office puts some numbers to the common knowledge that commercial payers pay providers significantly more than Medicare fee for service. The consequences include lower taxable wages and escalating federal subsidies of health insurance.

The new therapy treats patients with unresectable or metastatic uveal melanoma.

The U.S. Food and Drug Administration approved the second COVID-19 vaccine known as Moderna. The approved vaccine will be marketed as Spikevax for the prevention of COVID-19 in individuals 18 years of age and older.

Price increases on promising non–small cell lung cancer drugs despite evidence price competition raise concerns about affordability.

Perfect score from Human Rights Campaign Foundation highlights health company's commitment to LGBTQ+ equality.

Although systemic therapy improves survival for patients with advanced unresectable hepatocellular carcinoma (HCC), uptake was low and dose reductions were common, according to a real-world Canadian study.

Regeneron Pharmaceuticals and Sanofi said they are voluntarily withdrawing their supplemental Biologics License Application (sBLA) for Libtayo (cemiplimab-rwlc) as a second-line treatment for patients with advanced cervical cancer.

African American patients had 2.54 times the adjusted odds of having one or more negative descriptors in their Electronic Health Record compared to White patients. However, this form of racial bias can be avoided with a simple solution.

Humira may sink even further in the drug spend rankings next year when six biosimilars are expected to hit the market.

The CMS saw good news in its annual report on the federal healthcare agency’s largest ACO program. The National Association of ACOs say the report shows the program is shrinking and needs changes.

More than $250 million worth of counterfeit and illegally resold versions of Gilead Sciences’ HIV medications Biktarvy (bictegravir, emtricitabine and tenofovir alafenamide) and Descovy (emtricitabine and tenofovir alafenamide) were distributed to pharmacies and patients.

In this episode, Peter Wehrwein, managing editor of Managed Healthcare Executive, speaks with Dr. Rodrigo Cerda. Dr. Cerda has been recently promoted to the position of senior vice president of health services and chief medical officer of Independence Blue Cross in Philadelphia. He is also a member of Managed Healthcare Executive’s editorial advisory board. Peter and Dr. Cerda discuss his new role at the Independence Blue Cross, what it means to be a chief medical officer at an insurer these days, valued-based care, social determinants of health, and, of course, the pandemic.

A 2022 report by the Department of Labor cites specific examples of health plans and health insurance issuers failing to ensure parity. For instance, a health insurance issuer covered nutritional counseling for medical conditions like diabetes, but not for mental health conditions such as anorexia nervosa, bulimia nervosa and binge-eating disorder.

A look inside six trends that will shape and influence care, planning and performance over the next year for health plans.